EMEA-002947-PIP01-20
Key facts
| Active substance |
Exebacase
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0537/2021
|
| PIP number |
EMEA-002947-PIP01-20
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Staphylococcus aureus bacteraemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
ContraFect Corporation
Email: clinicalstudies@contrafect.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|